Medicis Pharmaceuticals Corporation A
-
Excluding Large Research Expense, Medicis' 1Q Results Meet Expectations
Medicis MRX reported first-quarter results with ..... significant change to our fair value estimate. Medicis ' revenue growth stemmed primarily from ..... sales growth of 41.7% and 108.5% in Medicis ' non-acne dermatology and non-dermatology …
-
Medicis Pharmaceutical ( MRX ): Q1 EPS of $0.60 beats by $0.18. Revenue of $202M (+22% Y/Y) beats by $17M. Shares -0.4% AH. (PR)
Medicis Pharmaceutical ( MRX ): Q1 EPS of $0.60 beats by $0.18 . Revenue of $202M (+22% Y/Y) beats by $17M . Shares -0.4% AH. ( PR ) Post your comment!
-
Medicis Pharmaceuticals Corporation MRX Q1 2012 Earnings Call Transcript
Thank you for joining in the Medicis First Quarter 2012 Financial Results ..... on the Company's website at www. medicis .com in the Investor Relations section ..... three months ended March 31, 2012, Medicis reported revenues of approximately …
-
Medicis ([[ MRX ]] +2.5%) gains on positive comments out of Deutsche earlier this morning. Deutsche says that after meeting with management, it believes its product pipeline is strong, an the launch of ...
Medicis ( MRX +2.5% ) gains on positive comments out of Deutsche earlier this morning. Deutsche says that after meeting with management …
-
Dreams of retirement at Medicis …… Shacknai, chairman and chief executive of Medicis Pharmaceutical ( MRX ) got one of the latter kinds in 2011 ..... colorful approach to pay. We last footnoted Medicis in August, you may recall, to write ..... this week .) According to the proxy Medicis filed on Wednesday, Shacknai’s total …
-
Medicis' Graceway Acquisition Helps Offset Generic Solodyn Pressure
Medicis ' MRX fourth-quarter results slightly exceeded ..... performance for Dysport and Restylane, Medicis reported 27.5% and 39.9% year ..... Xeomin, remains a headwind, we think Medicis ' cosmetic portfolio, chemical differences …
-
Medicis Pharmaceutical ( MRX ): Q4 EPS of $0.56 beats by $0.03. Revenue of $180.7M (+0.6% Y/Y) in-line. (PR)
Medicis Pharmaceutical ( MRX ): Q4 EPS of $0.56 beats by $0.03 . Revenue of $180.7M (+0.6% Y/Y) in-line. ( PR ) Post your comment!
-
Medicis Pharmaceuticals Corporation MRX Q4 2011 Earnings Call Transcript
Thank you for joining in the Medicis Fourth Quarter and the Year-End 2011 Financial Results Conference ..... being recorded and webcast live on the Company's website at www. medicis .com in the Investor Relations section and will be available for …
-
Allergan Reports Fourth Quarter Results, Emerging Markets and Botox Support Growth
… entrance of Merz Pharmaceuticals' Xeomin into the neurotoxin market should pressure cosmetic market share for both Allergan and Medicis MRX . As we have stated in the past, we expect chemical differences, brand recognition, and Allergan's broad cosmetic portfolio …
-
Patience With Palomar Could Pay
… gutted to the same extent as aesthetics. Although large players with more of a pharmaceutical focus like Allergan ( AGN ) and Medicis ( MRX ) have held up reasonably well, that is in large part because a larger part of their business falls under the header of …